{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:09:05Z","timestamp":1791900545828,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1016\/j.amjmed.2005.06.005","type":"journal-article","created":{"date-parts":[[2005,8,26]],"date-time":"2005-08-26T07:22:41Z","timestamp":1125040961000},"page":"21-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"S","title":["Heparin-induced thrombocytopenia: clinical manifestations and management strategies"],"prefix":"10.1016","volume":"118","author":[{"given":"L. Bernardo","family":"Menajovsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2005.06.005_bib1","unstructured":"Barcelona R. Type II heparin-induced thrombocytopenia: new treatment options. Cleveland Clinic Center for Continuing Education Pharmacotherapy Update. 2001;4. Cleveland Clinic Web site. Available at: http:\/\/www.clevelandclinicmeded.com\/medical_info\/pharmacy\/septoct2001\/thrombocytopenia.htm. Accessed July 23, 2004."},{"key":"10.1016\/j.amjmed.2005.06.005_bib2","unstructured":"Royal College of Pathologists of Australasia (RCPA) Manual, version 4.0, updated March 12 2004. Heparin-induced thrombocytopenia (HIT). Royal College of Pathologists of Australasia Web site. Available at: http:\/\/www.rcpamanual.edu.au\/sections\/clinicalproblem.asp?s=25&i=301. Accessed August 4, 2004."},{"key":"10.1016\/j.amjmed.2005.06.005_bib3","unstructured":"Riley RS. Heparin-induced thrombocytopenia (HIT): frequently asked questions. Virginia Commonwealth University Web site. Available at: http:\/\/www.pathology.vcu.edu\/clinical\/HIT_FAQ.pdf. Accessed July 23, 2004."},{"issue":"suppl 1","key":"10.1016\/j.amjmed.2005.06.005_bib4","first-page":"69","article-title":"Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs","volume":"30","author":"Walenga","year":"2004","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.amjmed.2005.06.005_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0037-1614206","article-title":"Heparin-induced thrombocytopenia: towards consensus","volume":"79","author":"Warkentin","year":"1998","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjmed.2005.06.005_bib6","unstructured":"Wallis DE, Warkentin TE. Understanding heparin-induced thrombocytopenia: historical and clinical perspectives [PowerPoint presentation]. CoagInfo.com: The Coagulation Information Source Web site. Available at: http:\/\/coaginfo.com\/files\/ss5\/understanding_Heparin_induced_thrombocytopenia.ppt. Accessed August 6, 2004."},{"key":"10.1016\/j.amjmed.2005.06.005_bib7","unstructured":"Trespalacios F. Grand rounds: heparin-induced thrombocytopenia [PowerPoint presentation]. Walter Reed Army Medical Hospital Web site. Available at: http:\/\/www.wramc.amedd.army.mil\/departments\/medicine\/Nephrology\/education\/Lectures\/HIT-2_files\/frame.htm. Accessed July 23, 2004."},{"key":"10.1016\/j.amjmed.2005.06.005_bib8","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/archinte.163.15.1849","article-title":"Argatroban anticoagulation in patients with heparin-induced thrombocytopenia","volume":"163","author":"Lewis","year":"2003","journal-title":"Arch Intern Med"},{"issue":"suppl 5","key":"10.1016\/j.amjmed.2005.06.005_bib9","first-page":"9","article-title":"Clinical presentation of heparin-induced thrombocytopenia","volume":"35","author":"Warkentin","year":"1998","journal-title":"Semin Hematol"},{"key":"10.1016\/j.amjmed.2005.06.005_bib10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1592\/phco.25.4.615.61036","article-title":"Early-onset heparin-induced thrombocytopenia after a 165-day heparin-free interval: Case report and review of the literature","volume":"25","author":"DeEugenio","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.amjmed.2005.06.005_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1378\/chest.122.1.37","article-title":"Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin","volume":"122","author":"Lubenow","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2005.06.005_bib12","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1517\/14656566.4.6.919","article-title":"Pharmacotherapy of heparin-induced thrombocytopenia","volume":"4","author":"Dager","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.amjmed.2005.06.005_bib13","doi-asserted-by":"crossref","first-page":"502","DOI":"10.7326\/0003-4819-135-7-200110020-00009","article-title":"Delayed-onset heparin-induced thrombocytopenia and thrombosis","volume":"135","author":"Warkentin","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2005.06.005_bib14","doi-asserted-by":"crossref","first-page":"804","DOI":"10.7326\/0003-4819-127-9-199711010-00005","article-title":"The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia","volume":"127","author":"Warkentin","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2005.06.005_bib15","series-title":"Heparin-Induced Thrombocytopenia","first-page":"335","article-title":"Treatment of heparin-induced thrombocytopenia: an overview","author":"Greinacher","year":"2004"},{"key":"10.1016\/j.amjmed.2005.06.005_bib16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/107602960200800406","article-title":"Risk factors and long-term follow-up of patients with the immune type of heparin-induced thrombocytopenia","volume":"8","author":"Lindhoff-Last","year":"2002","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.amjmed.2005.06.005_bib17","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1001\/archinte.1989.00390100095022","article-title":"Thrombocytopenia associated with heparin-coated catheters in patients with heparin-associated antiplatelet antibodies","volume":"149","author":"Laster","year":"1989","journal-title":"Arch Intern Med"},{"issue":"suppl 5","key":"10.1016\/j.amjmed.2005.06.005_bib18","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1093\/ajhp\/60.suppl_5.S5","article-title":"Overview of heparin-induced thrombocytopenia","volume":"60","author":"Spinler","year":"2003","journal-title":"Am J Health Syst Pharm."},{"key":"10.1016\/j.amjmed.2005.06.005_bib19","series-title":"Heart Disease: A Textbook of Vascular Medicine.","first-page":"1809","article-title":"Hemostasis, Thrombosis, Fibrinolysis, and Cardiovascular Disease","author":"Fuster","year":"1997"},{"key":"10.1016\/j.amjmed.2005.06.005_bib20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1445-5994.1992.tb02796.x","article-title":"Heparin-induced thrombocytopenia","volume":"22","author":"Chong","year":"1992","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.amjmed.2005.06.005_bib21","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/archinte.163.20.2518","article-title":"An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients","volume":"163","author":"Warkentin","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2005.06.005_bib22","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1046\/j.1365-2141.2003.04363.x","article-title":"Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia","volume":"121","author":"Gruel","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.amjmed.2005.06.005_bib23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.7326\/0003-4819-136-3-200202050-00009","article-title":"Delayed-onset heparin-induced thrombocytopenia","volume":"136","author":"Rice","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2005.06.005_bib24","unstructured":"Levine RL. Heparin-induced thrombocytopenia: challenges of diagnosis and treatment. Physicians Weekly Online Surgery Edition [serial online]; July 19, 2004;1. Available at: http:\/\/www.physiciansweekly.com\/pc.asp?edition=2&issueid=151&questionid=153. Accessed July 23, 2004."},{"key":"10.1016\/j.amjmed.2005.06.005_bib25","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9343(96)00258-6","article-title":"A 14-year study of heparin-induced thrombocytopenia","volume":"101","author":"Warkentin","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2005.06.005_bib26","doi-asserted-by":"crossref","unstructured":"Greinacher A, Lubenow N. Heparin-induced thrombocytopenia. Orphanet Encyclopedia [publication online]; December 2003. Orphanet Web site. Available at: http:\/\/www.orpha.net\/data\/patho\/GB\/uk-HIT.pdf. Accessed April 6, 2005.","DOI":"10.1201\/9780203027363.ch11"},{"key":"10.1016\/j.amjmed.2005.06.005_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-0038-1651670","article-title":"Antibodies to macromolecular platelet factor 4\u2013heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases","volume":"73","author":"Amiral","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2005.06.005_bib28","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/ajcp\/104.6.648","article-title":"Comparison of PF4\/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia","volume":"104","author":"Arepally","year":"1995","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.amjmed.2005.06.005_bib29","first-page":"344","article-title":"The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia","volume":"69","author":"Chong","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2005.06.005_bib30","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJM199210013271407","article-title":"Interpreting hoofbeats: can Bayes help clear the haze?","volume":"327","author":"Pauker","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.06.005_bib31","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1161\/01.CIR.0000147537.72829.1B","article-title":"Heparin-induced thrombocytopenia","volume":"110","author":"Warkentin","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2005.06.005_bib32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJM197507312930513","article-title":"Nomogram for Bayes\u2019s theorem","volume":"293","author":"Fagan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.06.005_bib33","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jama.1994.03510330081039","article-title":"Users\u2019 guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients?","volume":"271","author":"Jaeschke","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.06.005_bib34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1345\/aph.16388","article-title":"Heparin-induced thrombocytopenia","volume":"32","author":"Gupta","year":"1998","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.amjmed.2005.06.005_bib35","first-page":"63","article-title":"Heparin-induced thrombocytopenia","volume":"1","author":"Warkentin","year":"2002","journal-title":"Curr Hematol Rep"},{"key":"10.1016\/j.amjmed.2005.06.005_bib36","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.116.5.1333","article-title":"Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia","volume":"116","author":"Wallis","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2005.06.005_bib37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archinte.164.1.66","article-title":"Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia","volume":"164","author":"Srinivasan","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2005.06.005_bib38","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/01.CIR.100.6.587","article-title":"Heparin-Associated Thrombocytopenia Study (HAT) investigators. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia","volume":"100","author":"Greinacher","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2005.06.005_bib39","first-page":"611","article-title":"The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results","volume":"15","author":"Mahaffey","year":"2003","journal-title":"J Invasive Cardiol"},{"key":"10.1016\/j.amjmed.2005.06.005_bib40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/01.CIR.99.1.73","article-title":"Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study","volume":"99","author":"Greinacher","year":"1999","journal-title":"Circulation"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305004407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305004407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:38:17Z","timestamp":1757579897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934305004407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S0002934305004407"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.06.005","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heparin-induced thrombocytopenia: clinical manifestations and management strategies","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}